US Residents
This site is intended for non-US residents only.

Use Prosigna to predict your patient’s Risk of Recurrence (ROR)*

Prosigna generates ROR from a proprietary algorithm1

  • Intrinsic subtypes are biologically and clinically distinct types of breast cancer that are characterized by different PAM50 gene expression signatures2,3
  • ROR is derived from a proprietary algorithm based on the PAM50 gene signature, intrinsic subtype, tumor size, nodal status, and proliferation score1
  • The gene expression profile of a patient’s tumor is compared to each of the defined intrinsic subtype gene signatures to determine the degree of similarity1
  • Proliferation score is determined by evaluating multiple genes within the proliferation pathway4
  • ROR is provided as a numerical score on a 0-to-100 scale that estimates the probability of distant recurrence over 10 years1
Risk of Recurrence (ROR) algorithm compares patient gene expression profile to intrinsic subtypes

*ROR score is Prosigna’s proprietary model for predicting risk of recurrence in a patient. Probability of recurrence cannot be guaranteed.

References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167. 3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. 4. Bastien RRL, Ebbert MTW, Boucher KM, et al. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: a direct comparison to Oncotype DX. Presented at: 47th American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL. Abstract 503. 5. Nielsen T, McDonald S, Kulkarni S, et al. Analytical reproducibility of the breast cancer intrinsic subtyping test and nCounter® Analysis System using formalin-fixed paraffin-embedded (FFPE) breast tumor specimens. Poster presented at: 102nd United States and Canadian Academy of Pathology Annual Meeting; March 2-8, 2013; Baltimore, MD. Abstract 2075. 6. Gnant M, Filipits M, Mlineritsch B, et al; Austrian Breast and Colorectal Cancer Study Group. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with HR+ early breast cancer (EBC): an ABCSG study. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Abstract P2-10-02.